S. 1096Introduced

Preserve Access to Affordable Generics and Biosimilars Act

Plain-English overview

What this bill does

Prohibit anticompetitive patent settlement agreements involving generic drugs and biosimilars, while requiring full certification of related manufacturer agreements to antitrust agencies

Key points

Require agreement certifications
Prohibit anticompetitive patent settlements
Authorize FTC enforcement
Revoke 180 day exclusivity

Current status

Where it stands

Status

Introduced

Latest action

2025-04-10 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.

Related context

Topics and policy areas

Select a topic to continue exploring related legislation, members, and committees.

Administrative law and regulatory procedures Civil actions and liability Competition and antitrust Contracts and agency Federal Trade Commission (FTC)Health Intellectual property Judicial review and appeals

Discovery signals

About these signals

Methodology

Impact and Momentum are relative discovery aids calculated by Legislation Lemur. They help you scan the congressional record; they are not predictions, endorsements, ideological ratings, or measures of policy importance.

Impact ScoreOverall observed legislative footprint and accumulated activity.

MomentumHow recently active or changing the bill appears in available data.

Full Text (PDF)Amendments

View on Congress.gov